Veru Enrolls First Patient in Phase III Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients

Veru, Inc. announced that it has enrolled the first patient in its Phase III clinical trial of sabizabulin, a novel, proprietary, oral cytoskeleton disruptor with anti-inflammatory and anti-viral properties, to combat the effects of COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2.